#37. The Money-Final Episode of the Tectonic Shift

2x Trillion dollar companies have already emerged from the use of these drugs’ shift into weightloss—Eli Lily and Novo Nordisk. These pharmaceutical giants have enormous potential not only to continue growing at a rate that rivals the largest technology companies in the world, but can displace billions of top line revenue from the makers of processed foods. 

As you may remember from my two episodes with Dr. Michael Greger, author of “How Not To Die”, I have a deep passion for plant based & whole food eating. Nothing angers me like the processing of wholesome ingredients…this distancing of real food from the day to day lives of everyday people. 

And of course, when we talk about money, we have to talk about medicaid, medicare, the National Health Service, and the costs to the taxpayer for all of these medications. 

But as Warren Buffet says, “price is what you pay, value is what you get”. If these GLP-1 drugs can reduce our caloric intake by up to 2/3…does it matter if we’re still just eating 2/3 less of mcDonalds, and not making meaningful changes in our diet? 

To discuss this and other issues, I”ve invited a good friend, Fred Ginnebaugh. Fred has led a 20 year career spanning engineering, sales, marketing, and investing roles across the medical device industry. He has most recently expanded into strategy and corporate development for some up and coming medical brands and I just knew he’d have the best point of view on how these drugs are changing the economic landscape underneath our society.